标题
Impact of HCV genotype on treatment regimens and drug resistance: a snapshot in time
作者
关键词
-
出版物
REVIEWS IN MEDICAL VIROLOGY
Volume 26, Issue 6, Pages 408-434
出版商
Wiley
发表日期
2016-07-12
DOI
10.1002/rmv.1895
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- How Generalizable Are the Results From Trials of Direct Antiviral Agents to People Coinfected With HIV/HCV in the Real World?
- (2016) Sahar Saeed et al. CLINICAL INFECTIOUS DISEASES
- The importance of resistance to direct antiviral drugs in HCV infection in clinical practice
- (2016) Christoph Sarrazin JOURNAL OF HEPATOLOGY
- Global prevalence of pre-existing HCV variants resistant to direct-acting antiviral agents (DAAs): mining the GenBank HCV genome data
- (2016) Zhi-wei Chen et al. Scientific Reports
- Grazoprevir–Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection
- (2015) Stefan Zeuzem et al. ANNALS OF INTERNAL MEDICINE
- Susceptibilities of Genotype 1a, 1b, and 3 Hepatitis C Virus Variants to the NS5A Inhibitor Elbasvir
- (2015) Rong Liu et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Resistance Analysis of Baseline and Treatment-Emergent Variants in Hepatitis C Virus Genotype 1 in the AVIATOR Study with Paritaprevir-Ritonavir, Ombitasvir, and Dasabuvir
- (2015) Preethi Krishnan et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Prevalence of the hepatitis C virus NS3 polymorphism Q80K in genotype 1 patients in the European region
- (2015) Christoph Sarrazin et al. ANTIVIRAL RESEARCH
- Long-term follow-up of patients receiving boceprevir for treatment of chronic hepatitis C
- (2015) Anita Y.M. Howe et al. ANTIVIRAL RESEARCH
- High Cure Rate With 24 Weeks of Daclatasvir-Based Quadruple Therapy in Treatment-Experienced, Null-Responder Patients With HIV/Hepatitis C Virus Genotype 1/4 Coinfection: The ANRS HC30 QUADRIH Study
- (2015) Lionel Piroth et al. CLINICAL INFECTIOUS DISEASES
- Successful Retreatment of Chronic HCV Genotype-1 Infection With Ledipasvir and Sofosbuvir After Initial Short Course Therapy With Direct-Acting Antiviral Regimens
- (2015) Eleanor M. Wilson et al. CLINICAL INFECTIOUS DISEASES
- The Combination of Simeprevir and Sofosbuvir Is More Effective Than That of Peginterferon, Ribavirin, and Sofosbuvir for Patients With Hepatitis C–Related Child's Class A Cirrhosis
- (2015) Brian L. Pearlman et al. GASTROENTEROLOGY
- Efficacy of Sofosbuvir Plus Ribavirin With or Without Peginterferon-Alfa in Patients With Hepatitis C Virus Genotype 3 Infection and Treatment-Experienced Patients With Cirrhosis and Hepatitis C Virus Genotype 2 Infection
- (2015) Graham R. Foster et al. GASTROENTEROLOGY
- Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease
- (2015) Michael Charlton et al. GASTROENTEROLOGY
- No scientific basis to restrict 8 weeks of treatment with ledipasvir/sofosbuvir to patients with hepatitis C virus RNA
- (2015) Thomas R. O'Brien et al. HEPATOLOGY
- All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study
- (2015) David R. Nelson et al. HEPATOLOGY
- Hepatitis C virus drug resistance-associated substitutions: State of the art summary
- (2015) Erik Lontok et al. HEPATOLOGY
- Hepatitis C virus gene sequencing as a tool for precise genotyping in the era of new direct antiviral agents
- (2015) Francesca Ceccherini Silberstein et al. HEPATOLOGY
- Sofosbuvir for Chronic Hepatitis C Virus Infection Genotype 1–4 in Patients Coinfected With HIV
- (2015) Maribel Rodriguez-Torres et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Ombitasvir, Paritaprevir Co-dosed With Ritonavir, Dasabuvir, and Ribavirin for Hepatitis C in Patients Co-infected With HIV-1
- (2015) Mark S. Sulkowski et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Evaluation of sequencing of HCV core/E1, NS5A and NS5B as a genotype predictive tool in comparison with commercial assays targeting 5′UTR
- (2015) Adele L. McCormick et al. JOURNAL OF CLINICAL VIROLOGY
- Daclatasvir and asunaprevir plus peginterferon alfa and ribavirin in HCV genotype 1 or 4 non-responders
- (2015) Donald Jensen et al. JOURNAL OF HEPATOLOGY
- Sofosbuvir plus ribavirin for the treatment of chronic genotype 4 hepatitis C virus infection in patients of Egyptian ancestry
- (2015) Peter J. Ruane et al. JOURNAL OF HEPATOLOGY
- Sofosbuvir plus ribavirin for treating Egyptian patients with hepatitis C genotype 4
- (2015) Wahid Doss et al. JOURNAL OF HEPATOLOGY
- Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent
- (2015) Xavier Forns et al. JOURNAL OF HEPATOLOGY
- L159F and V321A Sofosbuvir-Associated Hepatitis C Virus NS5B Substitutions
- (2015) Evguenia S. Svarovskaia et al. JOURNAL OF INFECTIOUS DISEASES
- Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial
- (2015) Mark Sulkowski et al. LANCET
- Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study
- (2015) Jean-Michel Molina et al. LANCET
- Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4–5 chronic kidney disease (the C-SURFER study): a combination phase 3 study
- (2015) David Roth et al. LANCET
- Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial
- (2015) Christophe Hézode et al. LANCET
- Resensitizing daclatasvir-resistant hepatitis C variants by allosteric modulation of NS5A
- (2015) Jin-Hua Sun et al. NATURE
- Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis
- (2015) Michael P. Curry et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection
- (2015) Graham R. Foster et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection
- (2015) Jordan J. Feld et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1
- (2015) Susanna Naggie et al. NEW ENGLAND JOURNAL OF MEDICINE
- Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1
- (2015) David L. Wyles et al. NEW ENGLAND JOURNAL OF MEDICINE
- Consideration of Viral Resistance for Optimization of Direct Antiviral Therapy of Hepatitis C Virus Genotype 1-Infected Patients
- (2015) Julia Dietz et al. PLoS One
- Genetic Diversity and Selective Pressure in Hepatitis C Virus Genotypes 1–6: Significance for Direct-Acting Antiviral Treatment and Drug Resistance
- (2015) Lize Cuypers et al. Viruses-Basel
- Virologic Tools for HCV Drug Resistance Testing
- (2015) Slim Fourati et al. Viruses-Basel
- Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial
- (2015) Jürgen K Rockstroh et al. Lancet HIV
- Randomized, Placebo-Controlled, Single-Ascending-Dose Study of BMS-791325, a Hepatitis C Virus (HCV) NS5B Polymerase Inhibitor, in HCV Genotype 1 Infection
- (2014) Karen D. Sims et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Antiviral therapy of hepatitis C in 2014: Do we need resistance testing?
- (2014) Maximilian David Schneider et al. ANTIVIRAL RESEARCH
- Infrequent Development of Resistance in Genotype 1–6 Hepatitis C Virus–Infected Subjects Treated With Sofosbuvir in Phase 2 and 3 Clinical Trials
- (2014) Evguenia S. Svarovskaia et al. CLINICAL INFECTIOUS DISEASES
- Daclatasvir: The First of a New Class of Drugs Targeted Against Hepatitis C Virus NS5A
- (2014) I. Gentile et al. CURRENT MEDICINAL CHEMISTRY
- Treatment of HCV infection with the novel NS3/4A protease inhibitors
- (2014) Andrea De Luca et al. CURRENT OPINION IN PHARMACOLOGY
- Sofosbuvir plus daclatasvir for post-transplant recurrent hepatitis C: Potent antiviral activity but no clinical benefit if treatment is given late
- (2014) Adriano M. Pellicelli et al. DIGESTIVE AND LIVER DISEASE
- New Hepatitis C Therapies: The Toolbox, Strategies, and Challenges
- (2014) Jean–Michel Pawlotsky GASTROENTEROLOGY
- Detection of a Sexually Transmitted Hepatitis C Virus Protease Inhibitor-Resistance Variant in a Human Immunodeficiency Virus–Infected Homosexual Man
- (2014) Sandra Franco et al. GASTROENTEROLOGY
- ABT-450, Ritonavir, Ombitasvir, and Dasabuvir Achieves 97% and 100% Sustained Virologic Response With or Without Ribavirin in Treatment-Experienced Patients With HCV Genotype 1b Infection
- (2014) Pietro Andreone et al. GASTROENTEROLOGY
- Kinetic Analyses Reveal Potent and Early Blockade of Hepatitis C Virus Assembly by NS5A Inhibitors
- (2014) David R. McGivern et al. GASTROENTEROLOGY
- Clinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for sofosbuvir
- (2014) Eric F. Donaldson et al. HEPATOLOGY
- Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection
- (2014) Hiromitsu Kumada et al. HEPATOLOGY
- Global distribution and prevalence of hepatitis C virus genotypes
- (2014) Jane P. Messina et al. HEPATOLOGY
- Sofosbuvir and Ribavirin for Hepatitis C in Patients With HIV Coinfection
- (2014) Mark S. Sulkowski et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- The need for a sequencing-based assay to supplement the Abbott m2000 RealTime HCV Genotype II assay: A 1 year analysis
- (2014) Marlin Benedet et al. JOURNAL OF CLINICAL VIROLOGY
- Deep sequencing: Becoming a critical tool in clinical virology
- (2014) Miguel E. Quiñones-Mateu et al. JOURNAL OF CLINICAL VIROLOGY
- Global epidemiology and genotype distribution of the hepatitis C virus infection
- (2014) Erin Gower et al. JOURNAL OF HEPATOLOGY
- Asymmetric Binding to NS5A by Daclatasvir (BMS-790052) and Analogs Suggests Two Novel Modes of HCV Inhibition
- (2014) James H. Nettles et al. JOURNAL OF MEDICINAL CHEMISTRY
- All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study
- (2014) Michael Manns et al. LANCET
- Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial
- (2014) Ira M Jacobson et al. LANCET
- Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study
- (2014) Eric Lawitz et al. LANCET
- Retreatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin
- (2014) Stefan Zeuzem et al. NEW ENGLAND JOURNAL OF MEDICINE
- Treatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin
- (2014) Jordan J. Feld et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection
- (2014) Nezam Afdhal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection
- (2014) Nezam Afdhal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sofosbuvir and Ribavirin in HCV Genotypes 2 and 3
- (2014) Stefan Zeuzem et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis
- (2014) Kris V. Kowdley et al. NEW ENGLAND JOURNAL OF MEDICINE
- ABT-450/r–Ombitasvir and Dasabuvir with or without Ribavirin for HCV
- (2014) Peter Ferenci et al. NEW ENGLAND JOURNAL OF MEDICINE
- Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection
- (2014) Mark S. Sulkowski et al. NEW ENGLAND JOURNAL OF MEDICINE
- ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis
- (2014) Fred Poordad et al. NEW ENGLAND JOURNAL OF MEDICINE
- Hepatitis C virus NS5A inhibitors and drug resistance mutations
- (2014) Shingo Nakamoto WORLD JOURNAL OF GASTROENTEROLOGY
- Hepatitis C virus reinfection incidence and treatment outcome among HIV-positive MSM
- (2013) Thomas C.S. Martin et al. AIDS
- HIV/hepatitis C virus-coinfected patients who achieved sustained virological response are still at risk of developing hepatocellular carcinoma
- (2013) Nicolás Merchante et al. AIDS
- The Increasing Burden of Mortality From Viral Hepatitis in the United States Between 1999 and 2007
- (2013) Kathleen N. Ly et al. ANNALS OF INTERNAL MEDICINE
- Persistence of Resistant Variants in Hepatitis C Virus-Infected Patients Treated with the NS5A Replication Complex Inhibitor Daclatasvir
- (2013) Chunfu Wang et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Evolution of Treatment-Emergent Resistant Variants in Telaprevir Phase 3 Clinical Trials
- (2013) James C. Sullivan et al. CLINICAL INFECTIOUS DISEASES
- Hepatitis C therapy with HCV NS5B polymerase inhibitors
- (2013) Vincent Soriano et al. EXPERT OPINION ON PHARMACOTHERAPY
- Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: Updated criteria and genotype assignment web resource
- (2013) Donald B. Smith et al. HEPATOLOGY
- Is genotype 3 of the hepatitis C virus the new villain?
- (2013) Nicolas Goossens et al. HEPATOLOGY
- Mixed genotype hepatitis C infections and implications for treatment
- (2013) Anna L. McNaughton et al. HEPATOLOGY
- Phylogeny and molecular evolution of the hepatitis C virus
- (2013) Paulina Jackowiak et al. INFECTION GENETICS AND EVOLUTION
- Association Between Sustained Virological Response and All-Cause Mortality Among Patients With Chronic Hepatitis C and Advanced Hepatic Fibrosis
- (2013) Adriaan J. van der Meer et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders
- (2013) Anna S. Lok et al. JOURNAL OF HEPATOLOGY
- Nucleotide polymorphisms in the 5′-UTR region of HCV can affect the ability of two widely used assays to assign an HCV genotype
- (2013) Michela Pollicita et al. JOURNAL OF VIROLOGICAL METHODS
- Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial
- (2013) Eric Lawitz et al. LANCET INFECTIOUS DISEASES
- Epidemiology and natural history of HCV infection
- (2013) Behzad Hajarizadeh et al. Nature Reviews Gastroenterology & Hepatology
- Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options
- (2013) Ira M. Jacobson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nucleotide Polymerase Inhibitor Sofosbuvir plus Ribavirin for Hepatitis C
- (2013) Edward J. Gane et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection
- (2013) Eric Lawitz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Analysis of boceprevir resistance associated amino acid variants (RAVs) in two phase 3 boceprevir clinical studies
- (2013) Richard J.O. Barnard et al. VIROLOGY
- Hepatitis C virus protease inhibitor-resistance mutations: Our experience and review
- (2013) Shuang Wu WORLD JOURNAL OF GASTROENTEROLOGY
- Antiviral activity and resistance of HCV NS5A replication complex inhibitors
- (2013) Min Gao Current Opinion in Virology
- The prevalence of cirrhosis and hepatocellular carcinoma in patients with human immunodeficiency virus infection
- (2012) George N. Ioannou et al. HEPATOLOGY
- The Molecular Basis of Drug Resistance against Hepatitis C Virus NS3/4A Protease Inhibitors
- (2012) Keith P. Romano et al. PLoS Pathogens
- In VitroActivity of BMS-790052 on Hepatitis C Virus Genotype 4 NS5A
- (2011) Chunfu Wang et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- A Sustained Virologic Response Reduces Risk of All-Cause Mortality in Patients With Hepatitis C
- (2011) Lisa I. Backus et al. Clinical Gastroenterology and Hepatology
- Directly acting antivirals against hepatitis C virus
- (2011) V. Soriano et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Evaluation of three different hepatitis C virus typing methods for detection of mixed-genotype infections
- (2011) Muhammad IDREES et al. Journal of Digestive Diseases
- Distinct Functions of NS5A in Hepatitis C Virus RNA Replication Uncovered by Studies with the NS5A Inhibitor BMS-790052
- (2011) R. A. Fridell et al. JOURNAL OF VIROLOGY
- Telaprevir for Retreatment of HCV Infection
- (2011) Stefan Zeuzem et al. NEW ENGLAND JOURNAL OF MEDICINE
- In Vitro Resistance Profile of the Hepatitis C Virus NS3/4A Protease Inhibitor TMC435
- (2010) O. Lenz et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Rapid Emergence of Protease Inhibitor Resistance in Hepatitis C Virus
- (2010) L. Rong et al. Science Translational Medicine
- Hepatitis C Treatment: current and future perspectives
- (2010) Saira Munir et al. Virology Journal
- Viral hepatitis and HIV co-infection
- (2009) Vincent Soriano et al. ANTIVIRAL RESEARCH
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now